BMJ 2002;324:59-60 ( 12 January )

Editorials

Gathering intelligence on antiplatelet drugs: the view from 30 000 feet

When combined with other information overviews lead to conviction

Papers p 71 Education and debate p 103

The first 150 words of the full text of this article appear below.

The efficacy of aspirin in the secondary prevention of myocardial infarction and stroke is widely accepted. The evidence which supports this perception includes its identification as an inhibitor of cyclo-oxygenase and platelet aggregation; identification of the major product of platelet cyclo-oxygenase as thromboxane A2, a vasoconstrictor and platelet agonist; the discovery that aspirin irreversibly acetylates cyclo-oxygenase, permitting cumulative inhibition by low doses of thromboxane A2 formation in the presystemic circulation; the discovery that thromboxane A2 biosynthesis is increased during ischaemic episodes of unstable angina; and the demonstration in individual, controlled, prospective double blind trials that aspirin reduces both myocardial infarction and death in unstable angina by 50%, whether given at 75 mg, 324 mg, or 1300 mg/day. 1 2

Following these discoveries Collins, Peto, Baigent, and their colleagues in Oxford organised the Antithrombotic Trialists' Collaboration to share data and permit overview analyses of controlled trials of antiplatelet drugs. At the time of the initial . . . [Full text of this article]
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

Journalistic ethics: an oxymoron?
BMJ 2002 324: i. [Full Text]

For Debate: Preventing atherosclerotic events with aspirin
John G F Cleland
BMJ 2002 324: 103-105. [Extract] [Full Text] [PDF]

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
Antithrombotic Trialists' Collaboration
BMJ 2002 324: 71-86. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

  • Michelson, A. D., Frelinger, A. L., Furman, M. I. (2006). Resistance to antiplatelet drugs. Eur Heart J Suppl 8: G53-G58 [Abstract] [Full text]  
  • Cutler, J. A., Thom, T. J., Roccella, E. (2006). Leading Causes of Death in the United States. JAMA 295: 383-384 [Full text]  
  • Burnakis, T. G., McQuillan, A., Eikelboom, J. W., Catella-Lawson, F., Reilly, M. P., FitzGerald, G. A. (2002). Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. NEJM 346: 1589-1590 [Full text]  
  • Sudlow, C., Sandercock, P., Warlow, C., Pignone, M., Mulrow, C. (2002). Antiplatelet therapy and atherosclerotic events. BMJ 324: 917-917 [Full text]  
Access jobs at BMJ Careers
Whats new online at Student BMJ